Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial investigating abemaciclib plus fulvestrant versus chemotherapy in HR-positive, HER2-negative metastatic breast cancer; study terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Phase 4 | Status: TERMINATED | Results posted: 2021-08-24